Clinical Trial Update: Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24 [Phase 3]

View source ↗

Summary

A Phase 3 trial update comparing olmesartan medoxomil to candesartan cilexetil for reducing BNP levels in chronic heart failure was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• OLMESARTAN MEDOXOMIL (olmesartan medoxomil)
• candesartan cilexetil (candesartan cilexetil)

Snippet

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Conditions: Chronic Heart Failure, High Blood B-type (or Brain) Natriuretic Peptide (BNP) Level | Phase 3 | Status: TERMINATED